Lod

Researchers are evaluating the safety and early effectiveness of SAR445877, a new drug given alone or with other cancer treatments, in adults aged 18 and older who have advanced solid tumors that cannot be surgically removed or have spread. This Phase 12 open-label study includes participants who have limited or no standard treatment options, aiming to find the best dose and assess how well SAR445877 works in different combinations. The study has two parts Part 1 focuses on gradually increasing doses of SAR445877 given intravenously every one or two weeks to find safe and effective doses alone or with other therapies like cetuximab, ADG126, or bevacizumab. Part 2 expands to multiple groups testing SAR445877 at recommended doses, either alone or combined with these other anticancer drugs, in various cancer types such as melanoma, non-small cell lung cancer, colorectal, gastric, and liver cancers. Participants undergo a screening period of up to 28 days before starting treatment, which continues until the cancer progresses, unacceptable side effects occur, or other reasons require stopping. After treatment ends, there is a follow-up period to monitor outcomes until disease progression, new therapy, death, or withdrawal. Throughout the study, researchers collect safety data, tumor response measures, drug levels in the body, and immune responses to evaluate the effects of SAR445877 and combinations for up to two years.

This research aims to explore the relationship between brain activity measured by electroencephalography EEG and functional magnetic resonance imaging fMRI. The study focuses on correlating the connectivity observed in EEG with brain network connectivity seen with fMRI, enhancing understanding of brain function through integrating these two methods. The study is investigative and involves adults who have previously undergone brain MRI scans. Participants will undergo EEG evaluation using a dry electrodes headset to capture electrical brain activity. The EEG data will be processed to remove noise and artifacts and analyzed for frequency bands, oscillations, and power distribution. Functional connectivity analysis of EEG signals will be compared with fMRI connectivity across different brain regions and EEG frequency bands, including event-related potentials and synchronization. During the study, participants will complete EEG testing and data collection. Researchers will assess correlations between EEG and fMRI findings, anatomical MRI results, and clinical or cognitive measures. The primary outcome is the correlation of EEG and fMRI functional connectivity over approximately 24 months from the first to last participant. Safety and cooperation during EEG are monitored, and the total participation involves a single EEG evaluation after prior MRI.

Researchers are evaluating hyperbaric oxygen therapy HBOT for patients experiencing persistent symptoms of post stroke depression PSD, a common condition affecting about one-third of stroke survivors. PSD can slow recovery from stroke-related motor and cognitive problems and increase the risk of further brain events. This study aims to assess HBOTs effect on depression in these patients through a randomized, double-blind, sham-controlled design. Participants will receive either HBOT or a sham treatment over 60 daily sessions, five times a week for three months. Each HBOT session involves breathing 100% oxygen at increased pressure for 90 minutes with periodic air breaks. The sham group experiences similar conditions but breathes normal air at lower pressure to mimic the treatment experience. After treatment, participants enter a three-month follow-up period without intervention. During the study, participants will undergo various assessments including depression scales, cognitive tests, brain imaging MRI and fMRI, neurological evaluations, and inflammatory markers. These measurements will be taken before, immediately after the intervention, and at several points during follow-up to monitor changes. The primary outcome focuses on changes in PSD symptoms immediately after treatment, with safety and quality of life also carefully tracked throughout the study period.

Researchers are investigating the long-term effects of hyperbaric oxygen therapy on cognitive function in patients who have suffered traumatic brain injury TBI. This observational study focuses on individuals treated with hyperbaric chamber therapy between one and four years ago, aiming to evaluate changes in cognitive abilities and quality of life. The study is motivated by previous findings suggesting that hyperbaric oxygen may improve brain function through neuroplasticity, but long-lasting effects require further examination. Participants in this study have completed at least 60 hyperbaric oxygen therapy sessions at the Sagol Center for Hyperbaric Medicine and Research. The study involves a single assessment visit where participants provide consent, complete computerized cognitive tests, and answer validated questionnaires. Researchers will also collect and compare cognitive test results performed before and after the hyperbaric treatment series, along with demographic and medical history information. During the study visit, participants undergo computerized cognitive assessments and fill out questionnaires related to cognitive function, quality of life, and post-concussion symptoms. Data from previous evaluations and medical records will be reviewed to track changes over time. The study measures outcomes using tools like the NeuroTrax cognitive battery, CANTAB cognitive battery, and health surveys. Participation lasts up to 12 months, focusing on understanding the sustained impact of hyperbaric oxygen therapy on brain injury recovery.

Researchers are evaluating the performance and safety of AnGelHA 2 filler for correcting moderate to severe wrinkles and folds and for facial contour remodeling in regular clinical practice. This post-market, prospective, non-interventional, open-label study includes adults over 18 years who choose to undergo non-surgical aesthetic procedures using AnGelHA 2. The study aims to observe how this filler works in routine use without changing standard treatment methods. Participants will receive at least one injection of AnGelHA 2, with their healthcare provider deciding the injection technique, volume, depth, and treated areas based on individual needs. Treatments can address a single area or multiple areas and may be repeated anytime during the study as part of normal care. The study does not interfere with how treatments are given and follows patients through their usual clinical visits. The study involves an initial visit at baseline and optional follow-up visits at 1, 3, 6, 9, and 12 months after treatment. Additional visits can occur if requested by the patient or deemed necessary. At each visit, safety will be assessed along with how well the treatment performs by evaluating each treated area and overall facial appearance. The main outcome measured is the number of participants who show improvement in the investigators Global Aesthetic Improvement Scale iGAIS up to 56 weeks after treatment.

Anterior cruciate ligament ACL rupture is a common sports injury that causes significant functional problems and delays return to sport. This trial investigates the effect of hyperbaric oxygen therapy HBOT on accelerating recovery following ACL reconstruction ACLR surgery. Researchers aim to evaluate whether HBOT can improve healing speed and quality after ACLR, based on promising results from animal studies and earlier human trials involving ligament injuries. Participants receive either active HBOT or sham HBOT over a 6-week period. The active treatment involves 30 sessions 5 sessions per week of 90 minutes breathing 100% oxygen at 2 atmosphere absolute ATA with brief air breaks. The sham treatment mimics the procedure but uses normal air at low pressure to simulate the sensation of pressure without the full oxygen exposure. Both treatments use a multiplace hyperbaric chamber. During the study, participants undergo assessments including knee function questionnaires, MRI scans, ligament laxity tests, range of motion and edema measurements, pain ratings, muscle strength tests, and functional performance tests. Researchers measure changes from baseline immediately after the intervention. The trial monitors participants for up to about 6 weeks during treatment, with detailed functional and imaging evaluations to assess recovery progress. The lead sponsor is Assaf-Harofeh Medical Center.

Researchers are studying the effects of Hyperbaric Oxygen Therapy HBOT on circulating hematopoietic stem cells HSCs in the blood. Hematopoietic stem cells are responsible for producing all blood lineages and their number and function decline with age, contributing to biological aging. This study aims to evaluate how HBOT, which has been shown to increase stem cell proliferation and mobilization, affects these circulating stem cells in patients who are candidates for HBOT. The treatment involves sessions of HBOT lasting 90 minutes each, administered five times a week for at least 40 sessions. During each session, patients breathe 100% oxygen at 2 atmospheres absolute ATA pressure with five-minute air breaks every 20 minutes. The therapy is delivered using a multiplace hyperbaric oxygen chamber at a specialized medical center. Participants will provide blood samples to measure changes in hematopoietic stem cells before and immediately after the HBOT intervention. Researchers will assess the stem cell levels using blood tests and monitor changes from baseline as the primary outcome. The study includes adults aged 20 to 80 years who are starting HBOT for other reasons and who agree to blood sample collection. The total duration and follow-up details depend on the therapy schedule and outcome measurements.